Summarized by Masters of Longevity from Longevity Technology.
Maze Therapeutics will present clinical and preclinical kidney-disease research at a major nephrology meeting, previewing data on two investigational programs.
Key Takeaways
- Maze Therapeutics will present Phase 2 clinical results for MZE829 targeting APOL1-mediated kidney disease at ASN Kidney Week.
- The company will also present preclinical data on SLC6A19 inhibition suggesting reduced nephrotoxin uptake and protective proximal tubule metabolism.
- MZE829 is described as a dual-mechanism APOL1 inhibitor and MZE782 as an SLC6A19 inhibitor with potential relevance to kidney disease and metabolic disorders.
